October 23, 2016 12:51 AM ET


Company Overview of Sigma-Tau Pharmaceuticals, Inc.

Company Overview

Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company that focuses on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases in Canada. The company develops prescription pharmaceuticals, including Cystaran, a cysteamine ophthalmic solution; Carnitor levocarnitine tablets, oral solution, sugar-free oral solution, and injection; Carnitor, a levocarnitine injection; Matulane procarbazine hydrochloride capsules; Adagen, a pegademase bovine; Abelcet, an amphotericin B lipid complex injection; and DepoCyt, a cytarabine liposome injection. It also develops nonprescription medicines and dietary supplements. The company was foun...

9841 Washingtonian Boulevard

Suite 500

Gaithersburg, MD 20878

United States

Founded in 1980





Key Executives for Sigma-Tau Pharmaceuticals, Inc.

Chief Executive Officer
Vice President of Finance
Chief Executive Officer of Sigma-Tau Group
Senior Director of Legal Affairs & Compliance
Vice President of Medical Affairs
Compensation as of Fiscal Year 2016.

Sigma-Tau Pharmaceuticals, Inc. Key Developments

Sigma-Tau Pharmaceuticals, Inc. Appoints Michael Minarich as Chief Executive Officer

Sigma-Tau Pharmaceuticals, Inc. announced that its Board of Directors has appointed Michael Minarich as the company’s Chief Executive Officer (CEO), effective July 13, 2016. Mr. Minarich has served as interim Chief Executive Officer of the company since July 2015. He spent the previous 20 years as an expatriate in Asia (Seoul), Canada (Montreal) and Europe (Brussels & Prague) as the Market Company President, Czech Republic for Pharmacia Corporation and at legacy company, G.D. Searle /Monsanto, with increasing responsibilities in international General Management, Marketing and Business Development.

Sigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis

Sigma-Tau Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for the company's investigational compound, STP-206 (lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis), a live biotherapeutic being developed for the prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1,500 grams. The company is currently conducting a multi-center, double-blind, randomized, placebo-controlled Phase 1b/2a clinical trial for STP-206 at a number of different sites in the United States. An Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the beneficiary company with a seven-year period of U.S. marketing exclusivity if it is the first product to reach marketing approval, as well as potential tax credits for clinical research costs, federal grants, and a waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sigma-Tau Pharmaceuticals, Inc., please visit www.sigmatau.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.